Study to boost energy-making capacity in ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This Phase 2 trial tests a treatment meant to improve “energy production” in people with ALS. It aims to see whether increasing mitochondrial (cell energy) capacity can help ALS symptoms or progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ALS (based on the study doctor’s assessment).
- Your age is between 21 and 80 years.
- If you take riluzole for ALS, your dose must have been unchanged for at least 30 days.
- You can sign the study consent form and complete the study visits and tests.
- You do not have another major brain or nerve condition (like Alzheimer’s or Parkinson’s).
- You have not taken another experimental drug in the past 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ALN-SOD for people with ALS caused by a specific genetic mutation in the SOD1 gene. The goal is to see if it is safe and can help slow the disease.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This trial tests a new drug called XT-150 for ALS. The goal is to see if it is safe and how the body handles it. It may be an option if you have had ALS symptoms for up to 3 years and have good enough lung function.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
This trial tests whether a special high-calorie formula given through a PEG tube can help people with ALS maintain energy balance and potentially slow disease progression. It is for adults with ALS who are already using a PEG tube for nutrition.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.